Diagnoses of pathological gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced rates of pathological gambling, and thus positive outcomes1 · patients with pathological and problem gambling
CBT may leads to lower diagnoses of pathological gambling ‐ comparisons at 0 to 3 months… compared with control (low certainty).
1 finding from 1 review
Depression symptoms ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced depression symptoms, and thus positive outcomes1 · patients with pathological and problem gambling
1 finding from 1 review
Anxiety · patients with pathological and problem gambling
1 finding from 1 review
Gambling symptom severity · patients with pathological and problem gambling
1 finding from 1 review
Financial loss from gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced financial loss from gambling, and thus positive outcomes1 · patients with pathological and problem gambling
1 finding from 1 review
Frequency of gambling ‐ comparisons at 0 to 3 months post‐treatment Lower scores indicate reduced financial loss from gambling, and thus positive outcomes1 · patients with pathological and problem gambling
1 finding from 1 review
Pain Visual analog scale Scale from 0 to 100 (lower is better) · patients with Shoulder osteoarthritis
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus standard‐lower dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: 1. No clinically important improvement ‐ as measured by PANSS ‐ when compared with standard‐low dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in leaving the study early: any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens showed no clear difference in urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher… compared with placebo or no intervention (high certainty).
1 finding from 1 review
QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens showed no clear difference in quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) compared with placebo or no intervention (high certainty).
1 finding from 1 review
Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens in combination with other phytotherapy showed no clear difference in urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher… compared with placebo or no intervention (low certainty).
1 finding from 1 review
QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review